Comparative in vitro activity of the new quinolone fleroxacin (RO 23-6240).
RO 23-6240 (fleroxacin), pefloxacin, augmentin, cefaclor, cef-uroxime, ceftazidime, vancomycin, piperacillin and amikacin were tested against a wide variety of gram-positive and gram-negative bacteria. The MICs of fleroxacin were very similar to those of pefloxacin. Against all the bacterial groups tested, the quinolones compared favorably with the other antimicrobials tested, particularly against the more resistant species such as Corynebacterium group JK and D2 and methicillin-resistant staphylococci.
D000583:Amikacin / Q000494:pharmacology; D000658:Amoxicillin / Q000494:pharmacology; D019980:Amoxicillin-Potassium Clavulanate Combination; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D002433:Cefaclor / Q000494:pharmacology; D002442:Ceftazidime / Q000494:pharmacology; D002444:Cefuroxime / Q000494:pharmacology; D002939:Ciprofloxacin / Q000031:analogs & derivatives* / Q000494:pharmacology; D002969:Clavulanic Acids / Q000494:pharmacology; D003352:Corynebacterium / Q000187:drug effects; D004338:Drug Combinations / Q000494:pharmacology; D004352:Drug Resistance, Microbial; D016576:Fleroxacin; D009643:Norfloxacin / Q000031:analogs & derivatives / Q000494:pharmacology; D015366:Pefloxacin; D010878:Piperacillin / Q000494:pharmacology; D013210:Staphylococcus / Q000187:drug effects; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D002969:Clavulanic Acids; D004338:Drug Combinations; D015366:Pefloxacin; D002939:Ciprofloxacin; D002433:Cefaclor; D014640:Vancomycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D000583:Amikacin; D002442:Ceftazidime; D009643:Norfloxacin; D016576:Fleroxacin; D002444:Cefuroxime; D010878:Piperacillin